“The Buzz” Show: Merck (NYSE: MRK) Positive Data in Covid-19 Antiviral Drug Trial | Financial Buzz

“The Buzz” Show: Merck (NYSE: MRK) Positive Data in Covid-19 Antiviral Drug Trial

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Merck on the Rise After Revealing Positive Data in Covid-19 Antiviral Drug Trial”

Merck (NYSE: MRK) climbed over 8% in premarket trading after it and Ridgeback’s investigational oral antiviral medicine for COVID-19 was found to reduce the risk of hospitalization or death by approximately 50%.

Molnupiravir significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial and if authorized, could become the first oral antiviral medicine for COVID-19.

For over 130 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.

For more information, please visit: Merck

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!